Suma Krishnan (President, R&D) sold ~$129K of Krystal Biotech
Scheduled in advanceTraded Dec 4, 2025 · Filed Dec 5, 2025
A Krystal Biotech director sold $150K of Krystal Biotech shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$149,975
Shares × reported transaction price
31 days after results of Nov 3, 2025, 39 days before results of Jan 12, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.8% | −0.4% | +4.2% |
| 30 days | +5.3% | +0.9% | +4.4% |
| 90 days | +10.5% | −0.8% | +11.3% |
| 180 days | +28.9% | +8.1% | +20.8% |
Past results only. Not a forecast.
Suma Krishnan (President, R&D) sold ~$129K of Krystal Biotech
Scheduled in advanceSuma Krishnan (President, R&D) sold ~$304K of Krystal Biotech
Scheduled in advanceSuma Krishnan (President, R&D) sold ~$786K of Krystal Biotech
Scheduled in advance